The mystery of a medication that works but remains unexplained
In short: Mesalazine is a cornerstone of modern gastroenterology, yet its primary mechanism of action remains a scientific enigma. While it effectively treats inflammatory bowel disease by interacting directly with intestinal tissue, researchers are still piecing together the exact biochemical pathways that allow it to modulate the body's inflammatory response.
Ulcerative colitis and Crohn's disease are primarily managed using mesalazine (5-aminosalicylic acid), which received US medical clearance during 1987. It is classified as an aminosalicylate and an anti-inflammatory agent. While it is widely used for mildly to moderately severe cases, its efficacy is specifically noted for colonic diseases. It is so fundamental to treatment that it appears on the World Health Organization's List of Essential Medicines.
The drug's behavior in the body is complex. It is the active metabolite of several prodrugs, including sulfasalazine, balsalazide, and olsalazine. While it is often administered orally or rectally, it is believed to act locally on the colonic mucosa. However, its precise mechanism is not fully understood. Current scientific theories suggest it may decrease the synthesis of prostaglandins and leukotrienes—key components of inflammation—by modulating the cyclooxygenase and lipooxygenase pathways. More recent reports from 2025 even suggest it may bind tubulin and stabilize microtubules.
Despite its clinical success, mesalazine presents a nuanced safety profile. It is generally considered safe for use during pregnancy and breastfeeding, though it does cross the placenta and appears in breast milk. Conversely, it is contraindicated for children under two years of age, individuals with kidney disease, or those with aspirin allergies. While common side effects include nausea and headaches, rare but severe reactions like Stevens-Johnson syndrome have been documented. This gap between clinical utility and mechanistic clarity highlights a common phenomenon in pharmacology: a drug can be a life-changing tool before its internal 'instruction manual' is fully decoded.
Opens the Intellect+ feed with this card first. Swipe up for the next one.
Sources
- Summary by Intellect · source: Mesalazine
- Also: www.nhs.uk — Mesalazine: a medicine to treat inflammatory bowel conditions including ulcerative colitis and Crohn's disease
To cite this card, link to https://intellectplus.co.uk/app/science-mesalazine.
How we source, check and correct cards: Editorial standards.
General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.
Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?
Related
More in Biochemistry · More in Science · Latest · A–Z · All topics
